Plain-English translation of NCT06907797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a pilot study testing a new web-based application called TRIAL, which stands for Tools for Reducing Inequity in Acute Leukemia. The application is designed to make it easier for people with acute leukemia to find and enroll in clinical trials, especially for groups who have historically had fewer opportunities to participate in research. Researchers want to understand if this tool actually helps remove barriers and makes trials more accessible.
Not all patients with acute leukemia have equal access to clinical trials, and some groups face more barriers than others. This study exists to test whether a digital tool can help level the playing field and connect more people to potentially life-saving treatment options.
You likely qualify if…
You likely don't qualify if…
You would spend about 14 weeks in the study. At the beginning, you'll complete some questionnaires and have a baseline visit. Then you'll have access to the TRIAL web application for 14 days to explore clinical trial options. At the end, you'll fill out additional questionnaires about your experience. If you're selected, you may also participate in a brief recorded conversation with study staff to share your feedback on the tool.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Dana-Farber Cancer Institute
Collaborators
American Society of Clinical Oncology, National Cancer Institute (NCI)
Enrollment target
~75 participants
Started
April 2025
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Andrew Hantel, MD
Dana-Farber Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.